Klaus Sindahl

Klaus Sindahl has a diverse work experience spanning multiple industries. Klaus started their career in 2001 as an Auditor at Ernst & Young and worked there until 2003. In 2004, they joined TDC as a Project Controller and stayed there until 2006. During the same year, they also worked as an M&A Analyst at DSP Corporate Finance. In 2006, they joined Novozymes as an Acquisition Manager and later took on roles such as Project Manager & Executive Assistant and Senior Manager, Investor Relations until 2018. In 2018, they worked as a Business Development Director at Royal Unibrew. Currently, they hold the position of VP, Head of Investor Relations at Hansa Biopharma since 2019.

Klaus Sindahl's education history begins in 1995 when they attended Esbjerg Handelsskole. It is not specified what degree or field of study they pursued at this institution. In 1998, they enrolled at Syddansk Universitet - University of Southern Denmark, where they obtained a Bachelor of Science degree in Business Administration & Accounting, which they completed in 2001. Afterward, in 2003, Sindahl joined Copenhagen Business School, where they pursued a Master of Science degree in Finance, which lasted until 2006. During 2006, they attended Fudan University and focused on Chinese Politics & Economy for a short period of time. In 2010, Sindahl furthered their education by attending ICAEW and studying IFRS. Finally, in 2011, they attended MIT Sloan School of Management, where they studied Corporate Strategy.